40 results
424B5
NKTX
Nkarta Inc
25 Mar 24
Prospectus supplement for primary offering
8:15pm
supply of NK cells, improve the persistence of these cells for sustained activity in the body, engineer enhanced NK cell recognition of tumor targets
8-K
EX-99.1
NKTX
Nkarta Inc
25 Mar 24
Regulation FD Disclosure
6:05am
with a single cycle One cycle includes lymphodepletion and 3 doses of NKX019 Deep suppression achieved by day 30 NKX019 targets and kills C19+ cells
8-K
EX-99.1
NKTX
Nkarta Inc
8 Jan 24
Regulation FD Disclosure
8:50am
NKX019 targets and kills cells from patients across indications E:T Ratio NT control NKX019 n=3 patients n=1 patient n=3 patients n=3 patients In vitro
S-3/A
bd8ceca3 8xdie
24 Apr 23
Shelf registration (amended)
5:21pm
424B5
ul8 btplnd6zydlg
26 Apr 22
Prospectus supplement for primary offering
4:02pm
424B5
hjm65m 95ic4gox4tk
25 Apr 22
Prospectus supplement for primary offering
4:03pm
424B5
lmj54vy24pnjwyce0g
3 Sep 21
Prospectus supplement for primary offering
12:00am
S-3
o7bgh
12 Aug 21
Shelf registration
5:04pm